Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VT-EBV-N for Relapse Prevention in ENKL
NCT03671850Phase 2Unknown
- Sponsor
- ViGenCell Inc.
- Start
- Apr 2019
- Primary completion
- Dec 2023
- Modality
- Prophylactic Vaccines, Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
A Phase 2 trial of VT-EBV-N in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by ViGenCell Inc.. Status: unknown.
02
Drugs
VT-EBV-N
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT03671850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03671850.